Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Junshi Biosciences Co., Ltd. has received approval from the UK Medicines and Healthcare products Regulatory Agency for its drug Toripalimab, marketed as LOQTORZI® in the UK. This approval allows its use in combination therapies for treating nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC), marking it as a pioneering treatment in the UK for these cancers. The clinical trials demonstrated significant improvements in survival rates, highlighting the drug’s potential impact on patient outcomes.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.